Switching to DTG/3TC is non-inferior to continuing current antiretroviral regimen at week 48: SALSA subgroup analyses

被引：0

作者：

Taylor, S. ^{[1
]}

Andrade-Villanueva, J. F. ^{[2
]}

Kaplan, R. ^{[3
]}

Nahass, R. ^{[4
]}

Hocqueloux, L. ^{[5
]}

Scholten, S. ^{[6
]}

Di Giambenedetto, S. ^{[7
,8
]}

Galera, C. ^{[9
]}

Blair, L. ^{[10
]}

Wynne, B. ^{[10
]}

Oyee, J. ^{[11
]}

Underwood, M. ^{[10
]}

Curtis, L.

Bontempo, G. ^{[10
]}

van Wyk, J. ^{[12
]}

机构：

[1] Birmingham Heartlands Hosp, Birmingham, W Midlands, England

[2] Hosp Civil Fray Antonio Alcalde, Guadalajara, Mexico

[3] Desmond Tutu Hlth Fdn, Cape Town, South Africa

[4] IDCare, Hillsborough, North Ireland

[5] Ctr Hosp Reg Orleans, Orleans, France

[6] Praxis Hohenstaufenring, Cologne, Germany

[7] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCC, UOC Malattie Infett, Rome, Italy

[8] Univ Cattolica Sacro Cuore, Dipartimento Sicurezza & Bioet, Sez Malattie Infett, Rome, Italy

[9] Hosp Clinico Univ Virgen Arrixaca, Murcia, Spain

[10] ViiV Healthcare, Res Triangle Pk, NC USA

[11] GlaxoSmithKline, Uxbridge, Middx, England

[12] ViiV Healthcare, Brentford, England

来源：

HIV MEDICINE | 2021年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

PE2/72

引用

页码：129 / 129

页数：1

共 47 条

[1] Switching to DTG/3TC Is non-inferior to continuing a TAF-based regimen at week 144: TANGO subgroup analyses
Scholten, S.
Ajana, F.
Benson, P.
Kinder, C.
Smith, D. E.
Olalla Sierra, J.
Ait-Khaled, M.
Pappa, K. A.
Wang, R.
Wright, J.
Wynne, B.
Aboud, M.
van Wyk, J.
Smith, K. Y.
HIV MEDICINE, 2021, 22 : 128 - 129
[2] Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study
Ait-Khaled, M.
Nascimento, M. C.
Pappa, K. A.
Wang, R.
Wright, J.
Tenorio, A. R.
Wynne, B.
Aboud, M.
Gartland, M.
van Wyk, J.
HIV MEDICINE, 2019, 20 : 20 - 20
[3] Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA)
Llibre, J. M.
Alves, C.
Cheng, C-Y
Osiyemi, O.
Galera, C.
Hocqueloux, L.
Maggiolo, F.
Degen, O.
Blair, E.
Wynne, B.
Oyee, J.
Underwood, M.
Curtis, L.
Bontempo, G.
van Wyk, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 13 - 14
[4] Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR)
Rojas, J.
Blanco, J. L.
Negredo, E.
Domingo, P.
Tiraboschi, J.
Ribera, E.
Abdulghani, N.
Puig, J.
Mateo, G.
Podzamczer, D.
Gutierrez, M.
de Lazzari, E.
Paredes, R.
Martinez, E.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 110 - 110
[5] Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study)
van Wyk, J.
Ajana, F.
Bisshop, F.
De Wit, S.
Osiyemi, O.
Portilla, J.
Routy, J.
Wyen, C.
Ait-Khaled, M.
Nascimento, M.
Pappa, K.
Wang, R.
Wright, J.
Wynne, B.
Aboud, M.
Smith, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 14 - 15
[6] Archived resistance and response to <40 c/mL and TND-DTG/3TC FDC at week 48 in SALSA
Underwood, Mark
Osiyemi, Olayemi
Rubio, Rafael
Hocqueloux, Laurent
Porteiro, Norma
Degen, Olaf
Oyee, James
Horton, Joe
Parry, Chris
Wang, Ruolan
Sithamparanathan, Myooran
van Wyk, Jean
Wynne, Brian
Man, Choy
Blair, Elizabeth
Schneider, Martha
HIV MEDICINE, 2023, 24 : 45 - 46
[7] Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study)
Van Wyk, Jean
Ajana, Faiza
Bisshop, Fiona
De Wit, Stephane
Osiyemi, Olayemi
Portilla, Joaquin
Routy, Jean-Pierre
Wyen, Christoph
Ait-Khaled, Mounir
Nascimento, Maria-Claudia
Pappa, Keith A.
Wang, Ruolan
Wright, Jonathan
Wynne, Brian
Aboud, Michael
Smith, Kimberly Y.
HIV MEDICINE, 2021, 22 : 28 - 28
[8] Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG plus TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies
Orkin, C.
Porteiro, N.
Berhe, M.
Dretler, R.
Viciana, P.
Tseng, Y.
Oprea, C.
Johnson, M.
Kulagin, V.
Man, C.
Sievers, J.
Currie, A.
Underwood, M.
Tenorio, A.
Pappa, K.
Wynne, B.
Aboud, M.
Smith, K.
Gartland, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[9] Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection-48-week results from the GEMINI studies
Cahn, P.
Sierra Madero, J.
Arribas, J.
Antinori, A.
Ortiz, R.
Clarke, A.
Hung, C. -C.
Rockstroh, J.
Girard, P. -M.
Man, C.
Sievers, J.
Currie, A.
Underwood, M.
Tenorio, A.
Pappa, K.
Wynne, B.
Gartland, M.
Aboud, M.
Smith, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 156 - 156
[10] Switching to DTG+3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO Study)
van Wyk, J.
Ajana, F.
Bisshop, F.
De Wit, S.
Osiyemi, Y.
Portilla, J.
Routy, J. -P.
Wyen, C.
Ait-Khaled, M.
Nascimento, M.
Pappa, K.
Wang, R.
Wright, J.
Tenorio, A. -R.
Wynne, B.
Aboud, M.
Gartland, M.
Smith, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 102 - 103

← 1 2 3 4 5 →